clinical trial · NCT06304636

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

$RNAC →·phase1·terminated·n = 4

Refractory Multiple MyelomaRelapsed Multiple MyelomaDescartes-15

brief summary

This is a Phase I dose-escalation study to evaluate the safety, tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with Relapsed/Refractory Multiple Myeloma. The cell product is referred to as Descartes-15

started

Jun 19, 2024

primary completion

Apr 14, 2025

completion

Nov 13, 2025

last updated

Nov 24, 2025

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol